News stories about NeoGenomics (NASDAQ:NEO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NeoGenomics earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 44.9536121992529 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Great Discounts – Levitra Retail Price (thecommunityvoice.com)
- Canadian Health Inc – Cialis 2.5 Mg Daily (iheartguitarblog.com)
- New report examines the cancer biomarker market to grow at 14.07% CAGR during 2017-2025 (whatech.com)
- Trading Focus: Neogenomics Inc (NEO) Technical Levels in Review – Danville Daily (danvilledaily.com)
- Canadian Health Inc! Buy Viagra Manchester Uk (thecommunityvoice.com)
Several analysts recently commented on the company. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a research note on Wednesday, April 26th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a research note on Sunday, May 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.40.
NeoGenomics (NASDAQ:NEO) traded down 0.97% during mid-day trading on Friday, hitting $9.16. The company’s stock had a trading volume of 258,607 shares. NeoGenomics has a 52-week low of $6.90 and a 52-week high of $9.93. The firm’s market cap is $727.19 million. The firm has a 50 day moving average of $9.20 and a 200-day moving average of $8.26.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.03. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The company had revenue of $66.09 million for the quarter, compared to analyst estimates of $62.95 million. During the same quarter in the prior year, the business posted $0.04 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts expect that NeoGenomics will post $0.18 EPS for the current fiscal year.
In other NeoGenomics news, insider Steven A. Ross sold 70,833 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $7.76, for a total value of $549,664.08. Following the completion of the sale, the insider now owns 4,500 shares in the company, valued at approximately $34,920. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Alison L. Hannah acquired 20,000 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of $9.19 per share, with a total value of $183,800.00. Following the purchase, the director now owns 38,782 shares in the company, valued at approximately $356,406.58. The disclosure for this purchase can be found here. Insiders sold a total of 84,890 shares of company stock worth $665,707 in the last 90 days. 12.20% of the stock is currently owned by company insiders.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
What are top analysts saying about NeoGenomics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics Inc. and related companies.